News

New Study Validates Effectiveness of Oral Immunotherapy for Allergies

New Study Validates Effectiveness of Oral Immunotherapy for Allergies

Findings from a Pivotal Study on Food Allergies

Latitude Food Allergy Care recently revealed exciting results from a comprehensive study guided by Weill Cornell Medicine, which scrutinized the efficacy of oral immunotherapy (OIT) for food allergies. In a substantial sample of over 1,000 patients, the study reported a remarkable 91% of participants achieved the maintenance phase when treated in clinical environments.

Improving Clinical Practice

These findings are poised to illuminate a pressing need in food allergy management. Traditionally, food allergy treatment research has leaned heavily on controlled clinical trials; however, the latest results suggest OIT can be effectively administered in real-world clinical contexts. This represents a significant stride toward refining treatment protocols in food allergy care.

Real-World Impact

Dr. Zahida "Rani" Maskatia, an esteemed expert in the field, emphasized the importance of these findings, noting that they reflect the practical outcomes seen in everyday clinical practice rather than those observed in controlled studies. She stated, “This high success rate along with its safety profile raises confidence for healthcare professionals and families contemplating OIT as a viable treatment for food allergies.”

Study Highlights

The study made critical observations regarding patient reactions during OIT:

  • 91% of study participants reached maintenance for at least one food allergy.
  • 63% experienced some level of reaction, with a majority being mild in intensity, while 12.7% faced severe reactions.
  • In terms of frequency, reactions occurred in just 5% of all administered doses, with the bulk classified as mild.
  • The most frequently reported symptoms included pruritus (36%), mild abdominal discomfort (34%), and gastrointestinal disturbances like diarrhea (22%).
  • Notably, patients had a higher incidence of reactions to milk and egg allergies compared to other allergenic foods, such as sesame and peanuts.
  • Factors like lower respiratory issues and the age at which OIT began were linked to heightened chances of adverse reactions.

Poster Presentation Details

The comprehensive findings will be further elucidated in a poster session titled Factors Associated with Oral Immunotherapy-Related Reactions in Food Allergy Management: Insights from Clinical Practice during the upcoming American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

Event Schedule

  • Session Date and Time: March 1 at 9:45 AM
  • Presenter: Eirene Fithian, a medical student from Weill Cornell Medical College, alongside pediatric allergists Drs. Perdita Permaul and Priya Katari.
  • Poster Number: 433
  • Location: Convention Center, Ground Level, Hall A

Interacting at the Conference

Attendees at the AAAAI / WAO Joint Congress are encouraged to visit Latitude Food Allergy Care at Booth #855, located within the San Diego Convention Center, between February 28 and March 3, 2025, where clinicians will be available to discuss their research and answer any queries related to food allergy treatment.

About Latitude Food Allergy Care

Latitude Food Allergy Care stands out as the premier network of clinics specializing in the management of food allergies. Staffed by board-certified allergists, the facility employs cutting-edge diagnostics and evidence-based strategies, such as OIT, to devise personalized treatment plans for their patients. With a focus on quality care, Latitude is affiliated with a plethora of PPO insurance and various HMO plans across California and New York. Discover more about their services and updates on their website.

Frequently Asked Questions

What is the significance of the recent study on OIT?

The study highlights the effectiveness of oral immunotherapy in a real-world clinical setting, showing a 91% success rate in reaching maintenance phase.

Who conducted the study?

The research was led by Weill Cornell Medicine, involving over 1,000 patients treated with oral immunotherapy.

What were the common reactions noted in the study?

Common reactions included mild symptoms like pruritus and abdominal pain, with 12.7% of patients experiencing severe reactions.

When will the study findings be presented?

The findings are set to be presented during a poster session at the AAAAI Annual Meeting on March 1.

Where is Latitude Food Allergy Care located?

Latitude Food Allergy Care operates in multiple locations, particularly in California and New York, focusing on personalized treatment for food allergies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 147

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 59

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 114

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 19

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 131

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 76

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 139

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 72

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 147

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 141

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading

Top 5 Most Recently Viewed Articles

Trinseo Announces New Dividend Amid Strategic Changes Ahead

Updated Category News Views 225

Trinseo Approves Dividend for Shareholders Trinseo (NYSE: TSE), a prominent provider of specialty material solutions, has recently announced a quarterly dividend approved by its Board of Directors. The dividend declared stands at $0.01 per share, set to be distributed on a future date, offering a slight financial incentive for shareholders. To be eligible, shareholders...

Continue Reading
2026 Mighty 25: Celebrating Military Community Leaders

Updated Category News Views 26

A Spotlight on Unsung Heroes Tampa, Florida, just got a little mightier as We Are The Mighty rolls out the red carpet for the 2026 Mighty 25. This annual roll call, backed by CareSource Military & Veterans™, shines a light on veterans, military spouses, creators, entrepreneurs, and change agents defying the status quo. They are redefining impact across the military...

Continue Reading
Rubrik Inc Soars as Earnings Beat Expectations

Updated Category News Views 238

Rubrik Inc's Recent Stock Surge Rubrik, Inc. (NYSE: RBRK) has recently captured the attention of the market as its shares have risen over 20% following an impressive report of fourth-quarter earnings. The company exceeded expectations in both profitability and revenue, which undoubtedly prompted a wave of investor optimism. Financial Performance Highlights For the latest...

Continue Reading
Sanofi’s Amlitelimab Achieves Key Study Goals for Eczema Treatment

Updated Category News Views 284

Sanofi’s Amlitelimab Revolutionizes Atopic Dermatitis Treatment In an exciting development for patients suffering from atopic dermatitis, Sanofi's amlitelimab has met all primary and key secondary endpoints in the pivotal COAST 1 phase 3 study, targeting both adults and adolescents. This innovative medication demonstrated meaningful efficacy in terms of skin clearance...

Continue Reading
Alphamin Resources Corp: Board Changes and Future Outlook

Updated Category News Views 168

Leadership Changes at Alphamin Resources Corp Alphamin Resources Corp., a prominent player in the mining sector, recently shared significant news regarding its board of directors. The company announced the resignation of Mr. Rudolf Pretorius as a director. This change marks a pivotal moment in the company’s leadership structure, as Mr. Pretorius had been with the board...

Continue Reading